Older, Less Affluent Adults More Often Receiving an Opioid Prescription for Pain
Data for this study were sourced from the National Health Interview Survey (NHIS) which was conducted in 2019.
Data for this study were sourced from the National Health Interview Survey (NHIS) which was conducted in 2019.
Pharmacodynamic studies have shown that nalmefene has a longer duration of action than naloxone.
Past 30-day polysubstance use is reported by 32.6% of adults who seek substance use treatment in the United States.
The use of intravenous acetaminophen as first-line therapy for older adults with polytrauma reduced perioperative opioid use.
From 2016 to 2019, there was a decline in the percentage of patients receiving concurrent opioid and benzodiazepine prescriptions.
This cross-sectional geospatial analysis was conducted by investigators at the University of Chicago using the social vulnerability index data from the CDC and data from SAMHSA.
Twenty-three percent of AYAs with sarcoma who were previously opioid-naive and use opioids during treatment have new persistent opioid use after treatment.
Rapid opioid dose reduction or discontinuation exceeding existing pain management guidelines was linked to increased opioid-related harm risk.
For patients receiving concurrent chemoradiotherapy for squamous cell carcinoma of the head and neck, higher doses of gabapentin are well tolerated and associated with delayed time to first opioid use for additional pain control during radiotherapy.
Dsuvia, an opioid agonist, is a Schedule II controlled substance and is indicated for use in adults in a certified medically supervised healthcare setting.